| Objective To explore the effect of Gushukang capsule in the treatment of postmenopausal patients with osteoporotic intertrochanter fractures. Methods One hundred and eight postmenopausal patients diagnosed as osteoporotic intertrochanter fracture and met standard criteria in our hospital were enrolled from May 2012 to August 2016. They were randomly divided into Gushukang group and control group. All the patients received proximal femoral nail antirotation (PFNA) fixation for the treatment of intertrochanteric fractures. The patients in control group received alendronate and Caltrate. The patients in Gushukang group received 4 Gushukang capsules, 2 times daily on the basis of the control group. BMD of the lumbar spine and hip, serum levels of ALP, BGP, β-CTX, and PINP, hospital stay, fracture healing time, hip Harris score at final follow-up, and adverse reaction and complication during the treatment were recorded. Results BMD of the lumbar spine and hip in Gushukang group was higher than that in control group at 6 months after operation (P<0.05). The serum levels of ALP, BGP, β-CTX, and PINP in Gushukang group were lower than those in control group at 6 months after operation (P<0.05). The fracture healing time in Gushukang group was shorter than that in control group (P<0.05). The hospital stay and hip Harris score at final follow-up of two groups had no significant difference (P>0.05). There was no serious drug-related adverse reaction during the treatment. The total complication rate in Gushukang group and in control group was 3.51% and 15.69%, respectively, and the difference was statistically significant (χ2=4.180, P=0.041). Conclusion Gushukang capsule significantly reduces bone metabolic level, increases BMD, shortens fracture healing time, and reduces the complication rate in postmenopausal patients with osteoporotic intertrochanteric fracture without increasing complication rate. |